Morningstar® Stock Report™

Novo Nordisk A/S NOVO B

Letzte Unternehmensnews

DatumZeitQuelleTitelTyp
Previous Stories...
03.05.202417:48NASDAQNEWSNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
02.05.202405:30NASDAQNEWSNovo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024
01.05.202412:30NASDAQNEWSNovo Nordisk A/S - share repurchase programme
26.04.202410:16NASDAQNEWSNovo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024
24.04.202412:56NASDAQNEWSNovo Nordisk A/S - Articles of Association, April 2024
24.04.202412:56NASDAQNEWSVedtægter for Novo Nordisk, april 2024
24.04.202412:48NASDAQNEWSNovo Nordisk A/S – Reduction of the share capital
22.04.202413:06NASDAQNEWSNovo Nordisk A/S - share repurchase programme
15.04.202417:39NASDAQNEWSNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
15.04.202412:43NASDAQNEWSNovo Nordisk A/S - share repurchase programme
08.04.202413:40NASDAQNEWSNovo Nordisk A/S - share repurchase programme
02.04.202410:56NASDAQNEWSNovo Nordisk A/S - share repurchase programme
25.03.202411:58NASDAQNEWSNovo Nordisk A/S - share repurchase programme
25.03.202407:51NASDAQNEWSVedtægter for Novo Nordisk A/S 2024
25.03.202407:51NASDAQNEWSNovo Nordisk A/S - Articles of Association 2024
21.03.202415:55NASDAQNEWSAwiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities
21.03.202414:59NASDAQNEWSResolutions from the Annual General Meeting of Novo Nordisk A/S
18.03.202414:18NASDAQNEWSNovo Nordisk A/S - share repurchase programme
11.03.202412:46NASDAQNEWSNovo Nordisk A/S - share repurchase programme
08.03.202418:42NASDAQNEWSWegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease